LDCT in COVID-19 Pneumonia: a Prospective Moscow Study

Overview

Hypothesis: low-dose chest computed tomography, has the same accuracy for the diagnosis of pneumonia compared to the routine protocol. In total, 230 patients are planned to be enrolled in the study. Each patient will have 2 studies (routine chest CT and low-dose chest CT) sequentially during one visit to the computed tomography room.

Full Title of Study: “Low-dose Computed Tomography in COVID-19 Pneumonia: a Prospective Moscow Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 22, 2020

Detailed Description

As of 30 April 2020, there were over 3 million confirmed cases worldwide, of which over 200,000 were fatal. In Russia at the time of writing, 106 thousand cases of COVID-19 were registered in 78 regions, with 11619 recovered and 1073 dead. Initial prospective analysis of clinical data from 41 patients in Wuhan, with laboratory confirmation of the 2019-nCoV-2 virus, showed that 2019-nCoV-2 caused severe illness, clinically similar to SARS, which sometimes led to the need for hospitalization in the intensive care unit (13 out of 41 [32 %]) and death (6 out of 41 [15%]). All patients with pneumonia in this study had changes in the chest CT scan: preliminary reports indicated that all patients had bilateral lung infiltration. Given the current prevalence of the disease and the nonspecific symptoms, we expect a significant increase in chest CT scans shortly. A low-dose chest CT scan can be performed with an effective dose of no more than 3.5 mSv, which is much lower than the dose received with a standard protocol – 8-10 mSv. The investigators hypothesize that a patient with suspected pneumonia can have a low-dose chest CT scan instead of a standard CT while maintaining the accuracy of the method in the diagnosis of inflammatory pulmonary tissue infiltration. The advantage of participating in the study for the patient is the possibility of obtaining an image without motion artifacts that may be associated with coughing, possibly affecting the patient's management tactics. The study is intended to provide answers to the following questions: The primary point of the study is to evaluate the correlation between standard CT and low-dose CT scans for the detection of community-acquired pneumonia. The expected correlation percentage is 90%. The secondary point of study No. 1 is the threshold value of the infiltration zone size detected by low-dose CT scan compared to standard CT scan. Expected threshold – 10 mm. The secondary point of study No.2 is the number of infiltration zones of pulmonary parenchyma corresponding to viral pneumonia detected by low-dose CT scan in comparison with standard CT scan. Expected number – more than two zones. In the future, it is planned to use the obtained anonymized data to enter the international registers of images of pneumonia caused by COVID-19.

Interventions

  • Diagnostic Test: Low-dose Chest CT
    • Patients referred by the primary care physician with suspected pneumonia.

Arms, Groups and Cohorts

  • Active Comparator: Standard Chest CT
  • Experimental: Low-dose Chest CT

Clinical Trial Outcome Measures

Primary Measures

  • Evaluate the correlation between standard CT and low-dose CT scans for the detection of community-acquired pneumonia.
    • Time Frame: Upon completion, up to 1 year
    • A standardized scale CT1-CT4 will be used. The expected correlation percentage is 90%.

Secondary Measures

  • Threshold value of the infiltration zone size detected by low-dose CT scan compared to standard CT scan.
    • Time Frame: Upon completion, up to 1 year
    • Expected threshold – 10 mm.
  • Number of infiltration zones of pulmonary parenchyma corresponding to viral pneumonia detected by low-dose CT scan in comparison with standard CT scan.
    • Time Frame: Upon completion, up to 1 year
    • Expected number – more than two zones.

Participating in This Clinical Trial

Inclusion Criteria

  • A referral from the attending physician for a chest CT scan – Suspected pneumonia – Signed informed consent – Over 18 years old – Both male and female Exclusion Criteria:

  • Pregnant or nursing women – Presence of foreign implanted objects in the body at the scan level (including cardiac pacemakers, spine metalware) – Patients after surgical intervention at the level of the chest organs – Cancer patients

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department
  • Provider of Information About this Clinical Study
    • Principal Investigator: Sergey Morozov, Chief Research Officer – Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department

References

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum In: Lancet. 2020 Jan 30;:

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.